close
close
close
The pharmaceutical industry is characterized by innovation, international networking, and sensitive regulatory frameworks. Two countries stand out in Europe: Ireland and the United Kingdom. Both play a central role in the global pharmaceutical market but have developed different focuses and strategic functions – especially since Brexit. Ireland scores highly as a production and export location, while the UK is a center for research and regulatory innovation. A comparison shows how differently national strengths are utilized – and how they complement each other in a European context.
Over the past few decades, Ireland has developed into one of the most important pharmaceutical production locations worldwide. A significant proportion of global drug production, particularly in the area of high-quality biologics and sterile products, takes place here. Nearly all leading multinational pharmaceutical companies operate production facilities in the country, making the industry a key player in the economy and exports.
This position is based on several factors: a low corporate tax rate, stable political conditions, a highly skilled workforce, and a clear regulatory structure create an investment-friendly environment. As an EU member and the only English-speaking EU country, Ireland is particularly attractive to internationally active companies with a European focus. Ireland also offers direct access to the European single market. This is a key advantage that has become even more important after Brexit.
The United Kingdom has long been a key player in the European pharmaceutical market. Until 2019, the European Medicines Agency (EMA) was based in London and coordinated approvals for the entire EU. With Brexit, the UK has gained regulatory independence. The national authority MHRA (Medicines and Healthcare products Regulatory Agency) now operates independently of the European Medicines Agency, enabling more flexible and faster approval procedures – an advantage for pharmaceutical innovations and new therapies.
In addition, the UK has one of the world's leading research landscapes. Universities such as Oxford, Cambridge, and Imperial College are driving forward research in genomics, oncology, and data-driven drug discovery.
Ireland and the UK play different but complementary roles within the pharmaceutical value chain. Ireland stands for scalable production, supply chain stability, and secure EU market access. The UK, on the other hand, impresses with its strengths in research, clinical development, and regulatory flexibility.
This results in a clear strategic advantage for international pharmaceutical companies: production and export activities can be concentrated in Ireland, while innovation and development activities benefit from the UK system.
Ireland is the “factory” and the UK is the “laboratory” of the global pharmaceutical industry. Both locations remain central pillars of the European pharmaceutical landscape with clearly defined, complementary strengths. Companies that make targeted use of these differences can reduce regulatory risks, secure supply chains, and better exploit innovation potential.
